Novartis AG ADR (NVS)vsOrganogenesis Holdings Inc (ORGO)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
ORGO
Organogenesis Holdings Inc
$2.35
+2.17%
HEALTHCARE · Cap: $307.45M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 9929% more annual revenue ($56.58B vs $564.17M). NVS leads profitability with a 23.9% profit margin vs 6.6%. ORGO trades at a lower P/E of 15.9x. ORGO earns a higher WallStSmart Score of 67/100 (B-).
NVS
Buy51
out of 100
Grade: C-
ORGO
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+80.1%
Fair Value
$18.81
Current Price
$2.35
$16.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 78.1% year-over-year
Earnings expanding 555.0% YoY
Attractively priced relative to earnings
Strong operational efficiency at 28.9%
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Smaller company, higher risk/reward
6.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : ORGO
The strongest argument for ORGO centers on Price/Book, Revenue Growth, EPS Growth. Revenue growth of 78.1% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : ORGO
The primary concerns for ORGO are Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a declining stock while ORGO is a hypergrowth play — different risk/reward profiles.
ORGO carries more volatility with a beta of 1.48 — expect wider price swings.
ORGO is growing revenue faster at 78.1% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
ORGO scores higher overall (67/100 vs 51/100) and 78.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Organogenesis Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures and markets solutions for the advanced wound care and surgical and sports medicine markets in the United States. The company is headquartered in Canton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?